Evaluation of opioid-dependent prisoners in oral opioid maintenance therapy

Heroin Addiction and Related Clinical Problems

Volumn 12, Issue 1, 2010, Pages 5-16

  Metz, Verena ^a   Matzenauer, Christian ^a   Kammerer, Karin ^a   Winklbaur, Bernadette ^a   Ebner, Nina ^a   Radler, Dunja ^a   Fischer, Gabriele ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Buprenorphine; Methadone; Opioid addiction; Opioid maintenance therapy; Oral slow release morphines; Prisoners; Substance dependence

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; COCAINE; DIAMORPHINE; METHADONE; MORPHINE; OPIATE; OXAZEPAM;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CRIMINAL BEHAVIOR; DELINQUENCY; DISEASE DURATION; DRUG ABUSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TRAFFIC; DRUG USE; EUROPE; HEALTH STATUS; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; OPIATE ADDICTION; PATIENT SATISFACTION; PRIORITY JOURNAL; PRISON; PRISONER; QUALITY OF LIFE; SLOW DRUG RELEASE; SOCIAL INSURANCE; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

EID: 77950570885     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. AFSHAR P. (2007): Efficacy of harm reduction measures in prisons of Islamic Republic of Iran. Presentation at the 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
2. AUSTRIA PRESSE AGENTUR (2008). In: Der Standard: "Schwitzen statt sitzen" scheint sich zu bewähren. Available at http://derstandard.at/Text/Wii/?id=1216917909574. Accessed on January 14th, 2009.
3. BAUER S.M., LOIPL R., JAGSCH R., GRUBER D., RISSER D., THAU K., FISCHER G. (2008): Mortality in opioid-maintained patients after release from an addiction clinic. Eur Addict Res 14(2): 82-91.
4. BINSWANGER I.A., STERN M.F., DEYO R.A., HEAGERTY P.J., CHEADLE A., ELMORE J.G., KOEPSELL T.D. (2007): Release from prison - a high risk of death for former inmates. N Engl J Med 356(2): 157-165.
5. BLEICH A., GELKOPF M., SCHMIDT V., HAYWARD R., BODNER G., ADELSON M. (1999): Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic. Addiction 94(10): 1533-1540.
6. BOYS A., FARRELL M., BEBBINGTON P., BRUGHA T., COID J., JENKINS R., LEWIS G., MARSDEN J., MELTZER H., SINGLETON N., TAYLOR C. (2002): Drug use and initiation in prison: results from a national prison survey in England and Wales. Addiction 97: 1551-1560.
7. BRAMNESS J.G., KORNØR H. (2007): Benzodiazepine prescriptions for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 90(2-3): 203-209.
8. BROOKE D., TAYLOR C., GUNN J., MADEN A. (1998): Substance misusers remanded to prison - a treatment opportunity? Addiction 93(12): 1851-1856.
9. BUREAU OF JUSTICE STATISTICS (2007): Criminal Offenders Statistics. Available at http://www.ojp.usdoj.gov/bjs/crimoff.htm, last revised August 8, 2007. Accessed January 21st, 2008.
10. BUREAU OF JUSTICE STATISTICS (2007): Federal Justice Statistics. Available at http://www.ojp.usdoj.gov/bjs/fed.htm, last revised December 20, 2007. Accessed January 21st, 2008.
11. CANADIAN HIV/AIDS LEGAL NETWORK (2004): Prison needle exchange: lessons from a comprehensive review of international evidence and experience.
12. CDC (2001): Drug Use, HIV, and the Criminal Justice System. Available at http://www.cdc.gov/idu/factsdruguse.htm, last modified December 26th, 2007. Accessed January 21st, 2008.
13. DEMARIA P.A. Jr., STERLING R., WEINSTEIN S.P. (2000): The effect of stimulant and sedative use on treatment outcome of patients admitted to methadone maintenance treatment. Am J Addict 9(2): 145-153.
14. DOLAN K., RUTTER S., WODAK A.D. (2003): Prison-based syringe exchange programmes: a review of international research and development. Addiction 98(2): 153-158.
15. DOLAN K., WODAK A. (1996): An international review of methadone provision in prisons. Addiction Res 4(1): 85-97.
16. DOLE V.P., NYSWANDER M. (1965): A medical treatment for diacetylmorphine (heroin) addiction. JAMA 193: 80-84.
17. DOLE V.P., ROBINSON J.W., ORRACA J., TOWNS E., SEARCY P., CAINE E. (1969): Methadone treatment of randomly selected criminal addicts. N Engl J Med 280(25): 1372-1375.
18. DRUCKER E. (1999): Drug prohibition and public health: 25 years of evidence. Public Health Rep 114(1): 14-29.
19. EDER H, JAGSCH R., KRAIGHER D., PRIMORAC A., EBNER N., FISCHER G. (2005): Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 100(8): 1101-1109.
20. EMCDDA (2001): Annual report on the state of the drugs problem in the European Union. Office for Official Publications of the European Communities, Luxembourg.
21. EMCDDA (2002): Annual report on the state of the drugs problem in the European Union and Norway. Office for Official Publications of the European Communities, Luxembourg.
22. EMCDDA (2004): Public expenditure on drugs in the European Union. Office for Official Publications of the European Communities, Luxembourg.
23. ESHRATI B., ASL R.T., DELL C.A., AFSHAR P., MILLSON P.M., KAMALI M., WEEKES J. (2008): Preventing HIV transmission among Iranian prisoners: Initial support for providing education on the benefits of harm reduction practices. Harm Reduct J 5: 21.
24. FARLEY J., VASDEV S., FISCHER B., HAYDON E., REHM J., FARLEY T.A. (2005): Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health 95(10): 1737-1739.
25. FARLEY J.D., WONG V.K., CHUNG H.V., LIM E., WALTERS G., FARLEY T.A., YOSHIDA E.M. (2005): Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol 19(3): 153-156.
26. FARRELL M., MARSDEN J. (2007): Acute risk of drug-related death among newly released prisoners in England and Wales. Addiction 103: 251-255.
27. FAZEL S., BAINS P., DOLL H. (2006): Substance abuse and dependence in prisoners: a systematic review. Addiction 101(2): 181-191.
28. FEDERAL MINISTRY OF EDUCATION, ARTS AND CULTURE (2008): Grunddaten des österreichischen Schulwesens - Zahlenspiegel 2008. Available at http://www.bmukk.gv.at/medienpool/17604/zahlenspiegel_2008.pdf. Accessed on February 18th, 2009.
29. FEDERAL MINISTRY OF JUSTICE OF THE REPUBLIC OF AUSTRIA (2008): Anfragebeantwortung der Bundesministerin für Justiz 4606/AB (XXIII. GP). Available at http://www.parlinkom.gv.at/PG/DE/XXIIIAB/AB_04606/imfname_121563.pdf. Accessed on January 14th, 2009.
30. FISCELLA K., MOORE A., ENGERMAN J., MELDRUM S. (2005): Management of opiate detoxification in jails. J Addict Dis 24(1): 61-71.
31. FISCHER G, PETERNELL A., BALDINI A., BREZA A., EDER H., NIEDERMAYER I., TOPITZ A., HABERLER A., KRAIGHER D., KASPER S. (1998): Behandlung der Abhängigkeit von psychotropen Substanzen (Tätigkeitsprofil der Drogenambulanz). Allgemeines Krankenhaus der Stadt Wien, Wien.
32. GOMBAS W., FISCHER G., JAGSCH R., EDER H., OKAMOTO I., SCHINDLER S., MÜLLER C., FERENCI P., KASPER S. (2000): Prevalence and distribution of hepatitis C subtypes in patients with opioid dependence. Eur Addict Res 6(4): 198-204.
33. GOWING L., ALI R., WHITE J. (2006): Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2006(2):CD002025.
34. GRUBER V.A., DELUCCHI K.L., KIELSTEIN A., BATKI S.L. (2008): A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend 94(1-3): 199-206.
35. GSELLHOFER B., KÜFNER H., VOGT M., WEILER D. (1999): European Addiction Severity Index: EuropASI. Nach der 5. Auflage der amerikanischen Version von McLellan und Baltmannsweiler. Schneider Verlag, Hohengehren.
36. GUNTER T.D., ARNDT S., WENMAN G., ALLEN J., LOVELESS P., SIELENI B., BLACK D.W. (2008): Frequency of mental and addictive disorders among 320 men and women entering the Iowa prison system: use of the MINI-Plus. J Am Acad Psychiatry Law 36(1): 27-34.
37. HAIG T. (2003): Randomized controlled trial proves effectiveness of methadone maintenance treatment in prison. Can HIV AIDS Policy Law Rev 8(3): 48.
38. HENNEBEL L.C., STÖVER H., CASSELMAN J. (2005): Substitution treatment in European prisons. A study of policies and practices of substitution treatment in prison in 18 European countries. Heroin Add & Rel Clin Prob 7(2): 31-36.
39. HETLAND H., EIKELAND O.J., MANGER T., DISETH A., ASBJØRNSEN A. (2007): Educational background in a prison population. Journal of Correctional Education 58(2): 145-156.
40. KARIMINIA A., LAW M.G., BUTLER T.G., CORBEN S.P., LEVY M.H., KALDOR J.M., GRANT L. (2007): Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol 22: 417-428.
41. KINLOCK T.W., BATTJES R.J., SCHWARTZ R.P., THE MTC PROJECT TEAM (2002): A novel opioid maintenance program for prisoners: preliminary findings. J Subst Abuse Treat 22: 141-147.
42. KINLOCK T.W., BATTJES R.J., SCHWARTZ R.P.; MTC PROJECT TEAM (2005): A novel opioid maintenance program for prisoners: report of postrelease outcomes. Am J Drug Alcohol Abuse 31(3): 433-454.
43. KINLOCK T.W., GORDON M.S., SCHWARTZ R.P., O'GRADY K., FITZGERALD T.T. WILSON M. (2007): A randomized clinical trial of methadone maintenance for prisoners: results at 1-month postrelease. Drug Alcohol Depend 91(2-3): 220-227.
44. KINLOCK T.W., GORDON M.S., SCHWARTZ R.P., O'GRADY K.E. (2008): A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav 35(1): 34-47.
45. LAI S.H., YAO Y.J., LO D.S. (2006): A survey of buprenorphine related deaths in Singapore. Forensic Sci Int 162(1-3): 80-86.
46. LANGROD J., LOWINSON J., RUIZ P. (1981): Methadone treatment and physical complaints: a clinical analysis. Int J Addict 16(5): 947-952.
47. MAGURA S., ROSENBLUM A. (2001): Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 68(1): 62-74.
48. MAREMMANI I., PANI P.P., PACINI M., PERUGI G. (2007): Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenance-treated heroin-addicted patients. J Subst Abuse Treat 33(1): 91-98.
49. MARTYRES R.F., CLODE D., BURNS J.M. (2004): Seeking drugs or seeking help? Escalating "doctor shopping" by young heroin users before fatal overdose. Med J Aust 180(5): 211-214.
50. MASSON C.L., BARNETT P.G., SEES K.L., DELUCCHI K.L., ROSEN A., WONG W., HALL S.M. (2004): Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification. Addiction 99(6): 718-26.
51. MEGARBANE B., HREICHE R., PIRNAY S., MARIE N., BAUD F.J. (2006): Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences. Toxicol Rev 25(2): 79-85.
52. OLIVER J. (1991): The social care directive: development of a quality of life profile for use in community services for the mentally ill. Soc Work Soc Sci Rev 3: 5-45.
53. PRATT D., PIPER M., APPLEBY L., WEBB R., SHAW J. (2006): Suicide in recently released prisoners: a population-based cohort study. Lancet 368(9530): 119-123.
54. PRIEBE S., OLIVER J., KAISER W. (eds.) (1991): Quality of life and mental health care. Wrightson Biomedical Publishing, Petersfield UK.
55. REITOX NATIONAL FOCAL POINT (2005) Austria Drug Situation 2005. Report to the EMCDDA. Available at http://www.emcdda.europa.eu/html.cfm/index435EN.html. Accessed on July 27th, 2007.
56. SABBATINI S., GIULIANI R., MANFREDI R. (2006): Combinated pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz J Infect Dis 10(4): 274-278.
57. SARANG A., RHODES T., PLATT L., KIRZHANOVA V., SHELKOVNIKOVA O., VOLNOV V., BLAGOVO D., RYLKOV A. (2006): Drug injecting and syringe use in the HIV risk environment of Russian penitentiary institutions: qualitative study. Addiction 101(12): 1787-1796.
58. SEES K.L., DELUCCHI K.L., MASSON C., ROSEN A., CLARK H.W., ROBILLARD H., BANYS P., HALL S.M. (2000): Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 283(10): 1303-1310.
59. STALLWITZ A., STÖVER H. (2007): The impact of substitution treatment in prisons - a literature review. Int J Drug Policy 18(6): 464-474.
60. STARK K., HERRMANN U., EHRHARDT S., BIENZLE U. (2006): A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Epidemiol Infect 134(4): 814-819.
61. STERLING R.K., HOFMANN C.M., LUKETIC V.A., SANYAL A.J., CONTOS M.J., MILLS A.S., SHIFFMAN M.L. (2004): Treatment of chronic hepatitis C virus in the Virginia Department of Corrections: can compliance overcome racial differences to response? Am J Gastroenterol 99(5): 866-872.
62. STRANG J., GOSSOP M., HEUSTON J., GREEN J., WHITELEY C., MADEN A. (2006): Persistence of drug use during imprisonment: relationship of drug type, recency of use and severity of dependence to use of heroin, cocaine, and amphetamine in prison. Addiction 101(8): 1125-1132.
63. TAN J.A., JOSEPH T.A., SAAB S. (2008): Treating hepatitis C in the prison population is cost-saving. Hepatology 48(5):1387-1395.
64. WHO (2004): Best Practice in HIV/AIDS Prevention and Care for Injecting Drug Abusers: The Triangular Clinic in Kermanshah, Islamic Republic of Iran. World Health Organization, Geneva.